Skip to main content


Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Figure 8 | Journal of Biology

Figure 8

From: CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo

Figure 8

Chemotherapy decreases cell proliferation in the adult mouse CNS. Systemic exposure to cisplatin and BCNU was associated with profound changes in the number of BrdU-incorporating cells in the lateral SVZ, the DG and the CC. Animals were treated as described in Figure 5. The graphs show the percent-corrected values of BrdU+ cells per brain area normalized to the number of BrdU+ cells in sham-treated animals at various time points after systemic treatment with either BCNU or cisplatin. Data are means ± SEM. (a,b) Percent-corrected values of BrdU+ cells after (a) BCNU treatment or (b) cisplatin treatment. Bars labeled with an asterisk show statistically significant (P < 0.01) differences from control animals. (c) Immunoperoxidase staining for detection of BrdU+ cells in the lateral SVZ in representative sections from a 0.9% NaCl-injected control animal (C), one day (D1), and 42 days (D42) after systemic treatment with BCNU (3 × 10 mg/kg i.p.). (d) Diagrammatic representation of the part of the SVZ shown in (c) with adjacent part of the striatum (STR) and the overlying CC.

Back to article page